Compare INVE & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INVE | ANIX |
|---|---|---|
| Founded | 1990 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.7M | 100.6M |
| IPO Year | 1997 | 2013 |
| Metric | INVE | ANIX |
|---|---|---|
| Price | $3.86 | $2.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $5.50 | ★ $8.67 |
| AVG Volume (30 Days) | ★ 364.5K | 113.6K |
| Earning Date | 05-13-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.82 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $60,219,000.00 | $210,000.00 |
| Revenue This Year | $22.10 | N/A |
| Revenue Next Year | $20.74 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 7.21 | N/A |
| 52 Week Low | $3.08 | $2.44 |
| 52 Week High | $5.30 | $5.46 |
| Indicator | INVE | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 38.79 | 40.88 |
| Support Level | $3.23 | $2.44 |
| Resistance Level | $5.30 | $3.12 |
| Average True Range (ATR) | 0.33 | 0.15 |
| MACD | -0.16 | -0.04 |
| Stochastic Oscillator | 9.69 | 8.92 |
Identiv Inc develops specialty radio-frequency identification (RFID) and Internet of Things It (IoT) solutions that address customers' challenges and create new opportunities for them through the digitization and enhanced connectivity to the IoT. It designs, produces, and sells RFID and Bluetooth Low Energy (BLE) enabled devices, RFID inlays, tags, and labels that can be applied or incorporated into physical objects, providing them with a digital identity and the ability for customers to track, monitor, authenticate, and engage with consumers. Its IoT Business segment develops, manufactures, and supplies specialty IoT solutions tailored for the healthcare, logistics, smart packaging industries and other high-value end markets.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.